but anti-human antibodies for serological testing come with an additional specificity challenge, as customers may only want to detect either IgG, IgM or IgA, and not the other immunoglobulin isotypes.

IGM is doing so after imvotamab failed to deplete B cell counts — its therapeutic goal — as effectively as the company had hoped in early-stage tests in rheumatoid arthritis and lupus.

IGM Biosciences announced a strategic update to halt the development of two antibody therapies, imvotamab and IGM-2644, for autoimmune diseases due to insufficient results and strategic ...

Saliva-based diagnostics have emerged as a transformative approach in medical testing, offering a non-invasive and efficient ...

And IGM, as you mentioned ... which said they were infected -- -- if you now do a -- a rapid antigen or antibody test, and it's negative, then you should do it again. Because if that person ...

and commercialize IgM antibody agonists against immunology and inflammation targets. For more information, please visit www.igmbio.com. Cautionary Note Regarding Forward-Looking Statements This ...

The company now lists a lone, Sanofi-partnered IgM antibody asset on its pipeline ... it pivots from an in-house to outsourced analytical testing model. Those moves, coupled with other ...

IGM Biosciences announced they are halting the development of two investigational drugs for autoimmune and inflammatory diseases, imvotamab (an IgM-based CD20 X CD3 bispecific antibody T cell engager) ...

an IgM-based CD20 X CD3 bispecific antibody T cell engager, and IGM-2644, an IgM-based CD38 X CD3 bispecific antibody T cell engager, for autoimmune diseases. “Interim data from the Phase 1b studies ...